Transgenomic Launches NGS-Based Mitochondrial Disease Test, Developing Autism Risk Test | GenomeWeb

By Monica Heger

Transgenomic is taking a tentative step into the next-generation sequencing space with the launch of its Nuclear Mitome Test to diagnose mitochondrial disease. The test is initially being launched through the Seattle Children's Hospital on an Illumina HiSeq, but will later be offered through Transgenomic's Omaha, Neb.-based headquarters once the company acquires a next-gen sequencer, Transgenomic CEO Craig Tuttle told Clinical Sequencing News.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.